Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 10;608(7923):609–617. doi: 10.1038/s41586-022-05066-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, Centrally assessed best percentage change from the baseline in target lesion size of 115 (92%) of 125 individual patients with cholangiocarcinoma treated with pemigatinib, who had post-baseline scans. Data are from the FIGHT-202 study⁹ and the coloured bars indicate FGFR2-I17/E18 RE types and FGFR2 amplification status as diagnosed by FoundationOne. b, Objective tumour responses observed in the FIGHT-202 study assessed according to the Response Evaluation Criteria in Solid Tumours v.1.1 (RECIST 1.1) and grouped according to FGFR2 RE types/amplification status. No FGF/FGFR alterations (n = 17), FGFR2 in-frame fusion (n = 85), frame unknown RE (n = 12), intergenic space RE (n = 5), in-frame fusion + amplification (n = 5). ‘Not evaluable’ indicates that the patient was not evaluable for response using RECIST. c, Kaplan–Meier analysis of the progression-free survival of patients with cholangiocarcinoma treated with pemigatinib from the FIGHT-202 study and grouped according to FGFR2 RE types/amplification status. Data are median ± 95% CI for each cohort, and log-rank hazard ratios (HR) ± 95% CI for the indicated comparisons are shown. P values were calculated using log-rank (Mantel–Cox) tests. ND, not defined.

Source data